Form 4: ImmunityBio Insider Transactions: Patrick Soon-Shiong Converts Debt to Equity, Consolidates Notes

Patrick Soon-Shiong and related entities converted over $230 million in debt into ImmunityBio stock and consolidated existing promissory notes.

Summary

• Patrick Soon-Shiong, along with related entities including Nant Capital, converted a total of $230,679,022.30 and $30,723,395.57 of convertible promissory notes into 103,710,088 and 13,475,172 shares of ImmunityBio common stock respectively.
• These conversions occurred at prices of $1.935 and $2.28 per share respectively.
• Additionally, Nant Capital and ImmunityBio consolidated existing promissory notes into a single $505 million note.
• This consolidated note is convertible at a price of $5.427 per share.
• The transactions were executed on December 10, 2024.
• The reporting person, Patrick Soon-Shiong, holds shares both directly and indirectly through various entities.

Sentiment

Score: 6

Explanation: The document reflects a significant financial restructuring, which is a mixed bag. While reducing debt is positive, the potential dilution is a concern. The sentiment is neutral to slightly positive.

Positives

• The conversion of debt into equity strengthens the company's balance sheet by reducing liabilities.
• The consolidation of debt simplifies the company's financial structure.
• The conversion prices of $1.935 and $2.28 per share are above the recent low of the stock.

Negatives

• The conversion of debt into equity dilutes existing shareholders.
• The new consolidated note adds a significant amount of potential future dilution at a price of $5.427 per share.

Risks

• The potential for further dilution of existing shareholders if the consolidated note is converted.
• The large amount of debt held by Nant Capital could create future financial pressures.

Future Outlook

The document does not contain any specific forward-looking statements or guidance, but the conversion of debt to equity and the consolidation of notes will impact the company's future capital structure.

Management Comments

• Patrick Soon-Shiong is the Founder, Executive Chairman, and Global Chief Scientific and Medical Officer of ImmunityBio.

Industry Context

Debt conversions and restructurings are common in the biotech industry, especially for companies that are still in the development phase and not yet generating significant revenue. This transaction is a significant financial event for ImmunityBio.

Comparison to Industry Standards

• Similar debt-to-equity conversions are seen in other biotech companies such as Sorrento Therapeutics (SRNE) and Cassava Sciences (SAVA), where large debt holders convert debt into equity to reduce the company's debt burden and potentially benefit from future stock appreciation.
• The conversion prices are often negotiated based on the company's current stock price and future prospects, similar to the ImmunityBio transaction.
• The consolidation of debt is also a common practice to simplify the capital structure, as seen in companies like Ocugen (OCGN) which have restructured debt to improve their financial position.

Related Party Transactions

• The transactions involve Patrick Soon-Shiong and related entities, which are considered related party transactions.

Stakeholder Impact

• Shareholders will experience dilution due to the issuance of new shares.
• Creditors, specifically Nant Capital, have converted a significant portion of their debt into equity.
• The company's financial stability may improve due to the reduction in debt.

Next Steps

• The company will need to manage the potential dilution from the converted shares.
• The company will need to manage the potential future conversion of the consolidated note.

Key Dates

Keywords

ImmunityBio, IBRX, Patrick Soon-Shiong, Debt Conversion, Convertible Note, Equity, Insider Transaction, Nant Capital, Debt Restructuring